The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQVIA (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); MacroGenics (Inst); Mayne Pharma (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer Therapeutics Methods
Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Mark Voskoboynik
Honoraria - MSD
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Alpine Immune Sciences (Inst); Antengene (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Atridia (Inst); BeiGene (Inst); Hengrui Pharmaceutical (Inst); Hinova Pharmaceuticals (Inst); MSD (Inst); Virocure (Inst)
 
Ana Filipa Palma dos Reis
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Janssen; Pfizer
 
Anthony M. Joshua
No Relationships to Disclose
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Robert J. Jones
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Elsevier; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche/Genentech; Sanofi; WebMD
Consulting or Advisory Role - Myovant Sciences
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; IPSEN; Janssen; Merck Serono; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Exelixis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD
 
Pasquale Rescigno
Consulting or Advisory Role - AstraZeneca; MSD Italy
Travel, Accommodations, Expenses - AstraZeneca
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Caroline Kennedy
Employment - AstraZeneca
Stock and Other Ownership Interests - Amgen; AstraZeneca; GlaxoSmithKline
 
Spiros Linardopoulos
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Ganesh Moorthy
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
TJ Zhou
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jessica S Brown
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Edit Lukacs
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Richard Francis
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Andrew Hudson
Honoraria - AstraZeneca; Janssen; Novartis